Home
OCGN
OCGN News

Latest Ocugen Inc. (OCGN) News on July 26, 2024

Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy

GlobeNewswire

2 days ago

Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy

1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid

Motley Fool

15 days ago

1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid

Is Ocugen (OCGN) Stock Outpacing Its Medical Peers This Year?

Zacks

a month ago

Is Ocugen (OCGN) Stock Outpacing Its Medical Peers This Year?

MT Newswires

a month ago

Ocugen's Receives Nod to Enrol in High Dose Study of Stargardt Disease Drug Candidate

Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

GlobeNewswire

a month ago

Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication

GlobeNewswire

a month ago

Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Business Wire

2 months ago

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

GlobeNewswire

2 months ago

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

Share buy-back programme - week 23

GlobeNewswire

2 months ago

Share buy-back programme - week 23

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Simply Wall St.

2 months ago

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Japan's service sector mood hits nearly 2-year low in May

Reuters

2 months ago

Japan's service sector mood hits nearly 2-year low in May

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

AFP

2 months ago

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

GlobeNewswire

2 months ago

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

Enduring role of 'treasuring the past' hailed

PR Newswire

2 months ago

Enduring role of 'treasuring the past' hailed

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

Zacks

2 months ago

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

Ocugen (OCGN) Skyrockets 209.6% Year to Date: Heres Why

Zacks

2 months ago

Ocugen (OCGN) Skyrockets 209.6% Year to Date: Heres Why

MT Newswires

2 months ago

Ocugen Gets Recommendation For Dose Escalation in Eye Disease Trial; Shares Climb

Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy

GlobeNewswire

2 months ago

Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy

Ocugen to Present at BIO International Convention 2024

GlobeNewswire

2 months ago

Ocugen to Present at BIO International Convention 2024

Ocugen Set to Join Russell 3000® Index Effective June 28, 2024

GlobeNewswire

2 months ago

Ocugen Set to Join Russell 3000® Index Effective June 28, 2024

1 Stock That More Than Doubled This Year That I Wouldn't Touch With a 10-Foot Pole

Motley Fool

2 months ago

1 Stock That More Than Doubled This Year That I Wouldn't Touch With a 10-Foot Pole

Is Bicycle Therapeutics (BCYC) Outperforming Other Medical Stocks This Year?

Zacks

2 months ago

Is Bicycle Therapeutics (BCYC) Outperforming Other Medical Stocks This Year?

Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024

GlobeNewswire

2 months ago

Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024

MT Newswires

2 months ago

Ocugen Completes Dosing of Second Group in Stargardt Eye Therapy Safety and Efficacy Study

Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

GlobeNewswire

2 months ago

Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

GuruFocus.com

2 months ago

Ocugen Inc (OCGN) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances Amid ...

Thomson Reuters StreetEvents

2 months ago

Q1 2024 Ocugen Inc Earnings Call

Ocugen Provides Business Update with First Quarter 2024 Financial Results

GlobeNewswire

2 months ago

Ocugen Provides Business Update with First Quarter 2024 Financial Results

Associated Press Finance

2 months ago

Ocugen: Q1 Earnings Snapshot

Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

GlobeNewswire

3 months ago

Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

Ocugen to Present at May 2024 Investor Conferences

GlobeNewswire

3 months ago

Ocugen to Present at May 2024 Investor Conferences

Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results

GlobeNewswire

3 months ago

Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results

Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress

GlobeNewswire

3 months ago

Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress

Can Ocugen Stock Keep Churning Higher?

Motley Fool

3 months ago

Can Ocugen Stock Keep Churning Higher?

Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024

GlobeNewswire

3 months ago

Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024

Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?

Zacks

3 months ago

Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?

UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

GlobeNewswire

3 months ago

UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

GlobeNewswire

3 months ago

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy

GlobeNewswire

3 months ago

Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy

Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets

GlobeNewswire

3 months ago

Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

GlobeNewswire

4 months ago

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study

Zacks

4 months ago

Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication

GlobeNewswire

4 months ago

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy

GlobeNewswire

4 months ago

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy

Thomson Reuters StreetEvents

4 months ago

Q4 2023 Ocugen Inc Earnings Call

Ocugen (OCGN) Q4 2023 Earnings Call Transcript

Motley Fool

4 months ago

Ocugen (OCGN) Q4 2023 Earnings Call Transcript

Ocugen Provides Business Update with Certain Financials for the Year Ending 2023

GlobeNewswire

4 months ago

Ocugen Provides Business Update with Certain Financials for the Year Ending 2023

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease

GlobeNewswire

4 months ago

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease

Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023

GlobeNewswire

4 months ago

Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023

Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer

GlobeNewswire

4 months ago

Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410

GlobeNewswire

4 months ago

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410

Two Beaten-Down Stocks That Could Soar 170% and 630%, Respectively, According to Wall Street

Motley Fool

5 months ago

Two Beaten-Down Stocks That Could Soar 170% and 630%, Respectively, According to Wall Street

Ocugen to Present at Investing in Cures Summit

GlobeNewswire

5 months ago

Ocugen to Present at Investing in Cures Summit

Ocugen Clinical Showcase Webcast Now Available

GlobeNewswire

5 months ago

Ocugen Clinical Showcase Webcast Now Available

Meme Stock Meltdowns: 3 Names to Sell Before They Crash

InvestorPlace

5 months ago

Meme Stock Meltdowns: 3 Names to Sell Before They Crash

Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit

GlobeNewswire

5 months ago

Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit

Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST

GlobeNewswire

5 months ago

Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST

Ocugen to Present at 2024 BIO CEO & Investor Conference

GlobeNewswire

5 months ago

Ocugen to Present at 2024 BIO CEO & Investor Conference

Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024

GlobeNewswire

5 months ago

Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024

Ocugen to Present at Pharma Market Research Conference

GlobeNewswire

6 months ago

Ocugen to Present at Pharma Market Research Conference

REGISTER | WEBINAR INVITATION: Capital Link’s 2024 Virtual Corporate Presentation Series

GlobeNewswire

6 months ago

REGISTER | WEBINAR INVITATION: Capital Link’s 2024 Virtual Corporate Presentation Series

Middlefield Banc Corp. (MBCN) Reports Record Annual Net Income for 2023

GuruFocus.com

6 months ago

Middlefield Banc Corp. (MBCN) Reports Record Annual Net Income for 2023

FS Bancorp Full Year 2023 Earnings: EPS Beats Expectations

Simply Wall St.

6 months ago

FS Bancorp Full Year 2023 Earnings: EPS Beats Expectations

THIRD COAST BANCSHARES, INC. REPORTS RECORD 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

PR Newswire

6 months ago

THIRD COAST BANCSHARES, INC. REPORTS RECORD 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

Grindrod Shipping Holdings Ltd. Announces Ship Sales

GlobeNewswire

6 months ago

Grindrod Shipping Holdings Ltd. Announces Ship Sales

Associated Press Finance

6 months ago

FS Bancorp: Q4 Earnings Snapshot

FS Bancorp, Inc. Reports $36.1 Million of Net Income or $4.56 Per Diluted Share for 2023 and a 4% Increase in its Quarterly Dividend to $0.26 Per Share

GlobeNewswire

6 months ago

FS Bancorp, Inc. Reports $36.1 Million of Net Income or $4.56 Per Diluted Share for 2023 and a 4% Increase in its Quarterly Dividend to $0.26 Per Share

Bankwell Financial Group Reports Operating Results for the Fourth Quarter and Full Year 2023; Declares First Quarter Dividend

Business Wire

6 months ago

Bankwell Financial Group Reports Operating Results for the Fourth Quarter and Full Year 2023; Declares First Quarter Dividend

The RealReal, Inc. (NASDAQ:REAL) has caught the attention of institutional investors who hold a sizeable 45% stake

Simply Wall St.

6 months ago

The RealReal, Inc. (NASDAQ:REAL) has caught the attention of institutional investors who hold a sizeable 45% stake

CPSI Announces Divestment of American HealthTech to PointClickCare

Business Wire

6 months ago

CPSI Announces Divestment of American HealthTech to PointClickCare

Why WeightWatchers Stock Took a Dive Again Today

Motley Fool

6 months ago

Why WeightWatchers Stock Took a Dive Again Today

Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board

GlobeNewswire

6 months ago

Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board

ESQUIRE FINANCIAL HOLDINGS, INC. ANNOUNCES STRATEGIC FINTECH INVESTMENT IN PAYZLI

PR Newswire

6 months ago

ESQUIRE FINANCIAL HOLDINGS, INC. ANNOUNCES STRATEGIC FINTECH INVESTMENT IN PAYZLI

Primis Financial Corp. Announces Date for Fourth Quarter 2023 Earnings Release and Conference Call

PR Newswire

7 months ago

Primis Financial Corp. Announces Date for Fourth Quarter 2023 Earnings Release and Conference Call

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Zacks

7 months ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Analyst Blog Highlights Sunoco, New Gold, Hooker Furniture Corp., Molson Coors and NVIDIA

Zacks

7 months ago

The Zacks Analyst Blog Highlights Sunoco, New Gold, Hooker Furniture Corp., Molson Coors and NVIDIA

Medifast's (MED) Holistic Health Solution, Innovation Bode Well

Zacks

7 months ago

Medifast's (MED) Holistic Health Solution, Innovation Bode Well

Viasat (VSAT) Launches Data Plans for Small-Scale Enterprises

Zacks

7 months ago

Viasat (VSAT) Launches Data Plans for Small-Scale Enterprises

Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design

GlobeNewswire

7 months ago

Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design

Bit Digital, Inc. Announces Receipt of First Tranche of AI Servers

PR Newswire

7 months ago

Bit Digital, Inc. Announces Receipt of First Tranche of AI Servers

Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations

GlobeNewswire

7 months ago

Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations

Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury

Business Wire

7 months ago

Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

GlobeNewswire

7 months ago

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Urban One, Inc. (NASDAQ:UONE) Q2 2023 Earnings Call Transcript

Insider Monkey

8 months ago

Urban One, Inc. (NASDAQ:UONE) Q2 2023 Earnings Call Transcript

TTEC wins Talent Acquisition Team of the Year at OnCon Icon Awards

PR Newswire

8 months ago

TTEC wins Talent Acquisition Team of the Year at OnCon Icon Awards

Is There Now An Opportunity In Rimini Street, Inc. (NASDAQ:RMNI)?

Simply Wall St.

8 months ago

Is There Now An Opportunity In Rimini Street, Inc. (NASDAQ:RMNI)?

TELA Bio to Take Part in Connecting the Dots

GlobeNewswire

8 months ago

TELA Bio to Take Part in Connecting the Dots

Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference

GlobeNewswire

8 months ago

Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference

Investing in Park Aerospace (NYSE:PKE) five years ago would have delivered you a 37% gain

Simply Wall St.

8 months ago

Investing in Park Aerospace (NYSE:PKE) five years ago would have delivered you a 37% gain

Thomson Reuters StreetEvents

8 months ago

Q3 2023 Yatsen Holding Ltd Earnings Call

Yatsen (YSG) Q3 2023 Earnings Call Transcript

Motley Fool

8 months ago

Yatsen (YSG) Q3 2023 Earnings Call Transcript

Saba Capital Management, L.P. Bolsters Portfolio with Invesco Trust For Investment Grade New ...

GuruFocus.com

8 months ago

Saba Capital Management, L.P. Bolsters Portfolio with Invesco Trust For Investment Grade New ...

Ocugen, Inc. (NASDAQ:OCGN) Q3 2023 Earnings Call Transcript

Insider Monkey

9 months ago

Ocugen, Inc. (NASDAQ:OCGN) Q3 2023 Earnings Call Transcript

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease

GlobeNewswire

9 months ago

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease

ARIS MINING REPORTS Q3 2023 FINANCIAL AND OPERATING RESULTS: NET EARNINGS OF $12.4M, ADJUSTED EBITDA(1) OF $41.6M

PR Newswire

9 months ago

ARIS MINING REPORTS Q3 2023 FINANCIAL AND OPERATING RESULTS: NET EARNINGS OF $12.4M, ADJUSTED EBITDA(1) OF $41.6M

Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023

GlobeNewswire

9 months ago

Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023

ThredUp Inc. (NASDAQ:TDUP) Q3 2023 Earnings Call Transcript

Insider Monkey

9 months ago

ThredUp Inc. (NASDAQ:TDUP) Q3 2023 Earnings Call Transcript

Clover Health and WellBe Senior Medical Partner to Bring In-home Medical Care to Atlanta Patients and Across Rural Georgia

PR Newswire

9 months ago

Clover Health and WellBe Senior Medical Partner to Bring In-home Medical Care to Atlanta Patients and Across Rural Georgia

Investors Title Company Board Declares Special Cash Dividend and Regular Quarterly Cash Dividend

Business Wire

9 months ago

Investors Title Company Board Declares Special Cash Dividend and Regular Quarterly Cash Dividend

GCM Grosvenor Customized Infrastructure Strategies III Fund Holds Final Close as Firm Continues to See Strong Demand for Infrastructure Investments

GlobeNewswire

9 months ago

GCM Grosvenor Customized Infrastructure Strategies III Fund Holds Final Close as Firm Continues to See Strong Demand for Infrastructure Investments

Share on Social Networks: